Although there was no correlation between serum IL-31 levels at screening and pruritus VAS values at baseline, there was a tendency for patients with higher serum IL-31 levels at screening to have greater pruritus VAS reductions following nemolizumab treatment; this result was not observed in the placebo or NAL groups. Here, IL31 is linked to Pruritus.